Join Jeffrey M. Farma, MD and Anthony J. Olszanski, MD from Fox Chase Cancer Center as they present their multidisciplinary expertise on a range of cases pertaining to advanced melanoma.

The continuing development of novel immunotherapeutic and targeted agents for advanced melanoma has propelled the field to an exciting era. Immunotherapies harness the body’s natural immune system and have the potential to achieve a durable response in patients with metastatic melanoma. Treatment decisions for advanced melanoma are becoming increasingly complicated with the explosion of new agents that demonstrated survival benefits. As each agent requires careful initial selection as well as follow-up for specific side effects, clinicians need to be able to clearly discern and explain which agent or combination will best fit an individual patient based on tumor burden, symptoms, mutation status, and overall health.